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http://www.trialsjournal.com/content/14/1/263METHODOLOGY Open AccessDoes regional compared to local anaesthesia
influence outcome after arteriovenous fistula
creation?
Alan James Robert Macfarlane1*, Rachel Joyce Kearns1, Emma Aitken2, John Kinsella3 and Marc James Clancy2Abstract
Background: An arteriovenous fistula is the optimal form of vascular access in patients with end-stage renal failure
requiring haemodialysis. Unfortunately, approximately one-third of fistulae fail at an early stage. Different
anaesthetic techniques can influence factors associated with fistula success, such as intraoperative blood flow and
venous diameter. A regional anaesthetic brachial plexus block results in vasodilatation and improved short- and
long-term fistula flow compared to the infiltration of local anaesthetic alone. This, however, has not yet been
shown in a large trial to influence long-term fistula patency, the ultimate clinical measure of success.
The aim of this study is to compare whether a regional anaesthetic block, compared to local anaesthetic infiltration,
can improve long-term fistula patency.
Methods: This study is an observer-blinded, randomised controlled trial. Patients scheduled to undergo creation of
either brachial or radial arteriovenous fistulae will receive a study information sheet, and consent will be obtained in
keeping with the Declaration of Helsinki. Patients will be randomised to receive either: (i) an ultrasound guided
brachial plexus block using lignocaine with adrenaline and levobupivicaine, or (ii) local anaesthetic infiltration with
lignocaine and levobupivicaine.
A total of 126 patients will be recruited. The primary outcome is fistula primary patency at three months. Secondary
outcomes include primary patency at 1 and 12 months, secondary patency and fistula flow at 1, 3 and 12 months,
flow on first haemodialysis, procedural pain, patient satisfaction, change in cephalic vein diameter pre- and post-
anaesthetic, change in radial or brachial artery flow pre- and post-anaesthetic, alteration of the surgical plan after
anaesthesia as guided by vascular mapping with ultrasound, and fistula infection requiring antibiotics.
Conclusions: No large randomised controlled trial has examined the influence of brachial plexus block compared
with local anaesthetic infiltration on the long-term patency of arteriovenous fistulae. If the performance of brachial
plexus block increases fistulae patency, this will have significant clinical and financial benefits as the number of
patients able to commence haemodialysis when planned should increase, and the number of “redo” or revision
procedures should be reduced.
Trial registration: This study has been approved by the West of Scotland Research Ethics Committee 5 (reference no.
12/WS/0199) and is registered with the ClinicalTrials.gov database (reference no. NCT01706354).
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When chronic kidney disease (CKD) progresses to irre-
versible end stage renal failure, renal replacement therapy
(RRT) is necessary for survival [1]. Haemodialysis (HD) is
the commonest form of RRT. Good quality, stable vascular
access is a major factor in determining survival in this
group of CKD patients, and surgical creation of an
arteriovenous fistula (AVF) is recommended as the
optimal technique [2,3]. Unfortunately, approximately
one-third of arteriovenous fistulae fail at an early stage [4].
This failure rate is influenced by both the pre-operative
arterial and venous diameters and post-operative flow
through the AVF, as well as a number of other patient
and surgical factors [5,6]. Some anaesthetic techniques
can directly influence venous diameter as well as intra-
and post-operative blood flow [5], but there is no con-
clusive evidence as yet that any particular anaesthetic
technique can significantly influence long term surgical
outcome.
General anaesthesia, regional anaesthesia and local an-
aesthetic (LA) infiltration are all acceptable anaesthetic
techniques for AVF creation. Regional anaesthesia, such
as a brachial plexus block (BPB), involves injection of
LA around nerves to specifically ‘block’ the motor and
sensory nerves that supply the operative site, avoiding
the need for general anaesthesia. Whilst general anaes-
thesia increases intra-operative vasodilatation, CKD pa-
tients are known to be at increased risk of peri- and
post-operative complications [7,8]. Many of these com-
plications can be avoided if regional or local anaesthesia
are employed. Only regional anaesthesia, however, pro-
duces an associated sympathetic nerve block which re-
sults in an increased intraoperative venous diameter and
vessel flow, both intra-operatively and, for several hours,
post-operatively [9,10]. Maintenance of adequate blood
flow through the fistula post-operatively can help pre-
vent thrombosis and fistula failure and is important in
fistula maturation [10]. Furthermore, arterial and venous
spasm reduces flow and is more common with local
infiltration than regional (or general) anaesthesia [11].
Several non-randomised trials have already demon-
strated that, compared to local infiltration, a BPB results
in lower immediate AVF failure rates [6,12] and also an
improved surgical ability to identify the optimal graft site
[13]. The effects, however, of these short-term benefits of
regional anaesthesia on long-term AVF survival (patency)
remain uncertain. To date there has been no large-scale
randomised clinical trial examining this question. Recently
it has been demonstrated that a BPB compared to LA
alone significantly increased flow through the fistula up
until eight weeks after surgery, but this did not translate
into any difference in fistula patency [14]. Increased flow
is important, but ultimately it is the patency of the AVF
that is the major determinant of success. This trial wasunderpowered and the authors’ final conclusion was that
larger scale clinical trials were required.
Anaesthetic technique, therefore, has the potential to
modify a number of factors which may influence fistula
success. We wish to investigate whether anaesthetic tech-
nique can influence fistula patency. Given the higher risks
of general anaesthesia in these patients, we wish to com-
pare BPB and LA techniques in an adequately powered
trial. We hypothesise that the regional anaesthetic tech-
nique of an ultrasound guided BPB will, as a result of
improved vasodilation and blood flow at the time of and
shortly after surgery, increase the AVF patency rate at
three months compared to those undergoing the proced-
ure with LA infiltration. If this is the case, the number of
patients able to commence HD when planned should be
increased and the number of “redo” procedures should be
reduced. This has clear financial implications as well as
reducing inconvenience for patients.
Methods
Overview
This is a single centre, observer-blinded, randomised con-
trolled trial. This study has been approved by the West of
Scotland Research Ethics Committee 5 (reference no. 12/
WS/0199) and is registered with the ClinicalTrials.gov
database (reference no. NCT01706354). This study will
be performed in keeping with the requirements of the
Declaration of Helsinki.
Hypothesis
The creation of arteriovenous fistulae under ultrasound
guided brachial plexus block anaesthesia will result in an
increased primary patency rate at three months compared
to the use of local anaesthetic infiltration.
Objectives and outcome measures
This study aims to compare local anaesthetic infiltration
to a BPB anaesthetic technique for the surgical creation
of an AVF, assessing in particular whether an increase in
flow at the time of surgery with a BPB alters long-term
outcome. The primary outcome measure is AVF primary
patency at three months. Primary patency is defined as
the unequivocal clinical presence of a thrill or audible
bruit indicating flow through the fistula, in a fistula which
has not required intervention to maintain or re-establish
flow for whatever reason. Secondary outcomes include
immediate post-operative patency (within one hour of ter-
mination of the procedure), primary patency at one month
and one year, primary functional patency at three months
and one year (that is, primary patency as described previ-
ously but which is also able to deliver flow greater than
350 ml/minutes without recirculation for the duration of
haemodialysis), secondary patency at one year (that is,
patency maintained by other therapeutic interventions, for
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AVF at one month, three months and one year, flow rates
of the radial/brachial artery at one month, three months
and one year measured by ultrasound, flow obtained at
first HD, flow on HD after one year, change in cephalic
vein diameter pre-/post-anaesthetic, change in radial or
brachial artery flow pre-/post-anaesthetic, alteration of the
surgical plan after anaesthetic and then venous/arterial
mapping with ultrasound, AVF infection requiring
antibiotics, pain during the procedure, pain one hour
post-operatively, patient satisfaction, BPB success, compli-
cations including the requirement for conversion to gen-
eral anaesthesia, the requirement for additional sedation
or analgesics peri-operatively, post-operative paraesthesia
or weakness suggestive of nerve damage, pneumothorax
and time to perform the procedure.
Study centre
Our centre is a tertiary referral facility for vascular access
formation performing around 400 AVF creations per year.
The necessary volume of clinical cases, presence of clinical
expertise and equipment required for this study is well
established in this unit. There is a wealth of experience on
the use of ultrasound guidance for regional anaesthetic
techniques within the department [15-18].
Patients and enrolment
Patients scheduled to undergo primary AVF creation
will be invited to participate in the study during their
pre-assessment clinic visit staffed by the surgeon and
the pre-assessment anaesthetic nurse. Inclusion criteria
are English-speaking adults aged 18 to 85 who are compe-
tent to give consent scheduled for primary AVF formation
at either the radial or brachial artery. Exclusion criteria are
allergy to local anaesthetic, coagulopathy, infection at the
anaesthetic or surgical site, patient preference for general
or alternative anaesthesia, significant peripheral neur-
opathy or neurologic disorder affecting the upper extrem-
ity, pregnancy, previous AVF creation on the ipsilateral
arm, known cephalic vein occlusion, central vein stenosis,
brachial or radial artery stenosis and vein or artery less
than 1.8 mm, as measured by ultrasound.
Consent
The process of consent will be in accordance with the
Declaration of Helsinki. All suitable patients will be fully
informed that they are being asked to participate in a
research study. The procedures involved in the study,
and the chances of being assigned randomly to one of
two groups, will be explained in person and via an infor-
mation sheet approved by the West of Scotland Ethics
Committee. A signed consent form will be obtained from
each patient and retained by the investigators. Patients willbe made aware of their right to withdraw from the study
at any time without adverse effects on their clinical care.
Pre-operative management
At room temperature, in a supine position and without
any flexing of the elbow, the internal diameter of the
cephalic vein in all patients will be measured by a
blinded observer using a linear ultrasound probe at the
wrist and elbow. The internal diameter of the basilic
vein at the elbow will also be measured. In all cases,
minimal compression will be applied with the probe and
the vein measured in its most circular shape. To reduce
intra-observer variability, the average of three measure-
ments will be recorded for each parameter. Each vein
measurement position will be marked on the skin. Flow
through the radial artery or brachial artery, depending on
which is being used for the AVF, will also be measured
using Doppler ultrasound. In order to calculate flow, both
vessel cross sectional area and time averaged velocity
need to be measured. Cross sectional area is calculated
by the machine after using ultrasound to measure vessel
diameter. Time averaged velocity is measured in the
long access with Doppler ultrasound maintaining an
angle of insonation of less than 60 degrees. Using these
figures, flow can then be calculated [19]. Again, the
point of measurement will be marked on the skin and
an average of three measurements will be recorded to
reduce intra-observer variability.
Randomisation
A computer generated 1:1 allocation sequence (in random
permuted blocks of either four or six) will be created by
an independent operator who is not directly involved with
the study. Allocation concealment will be achieved using
sequentially numbered, sealed opaque envelopes. An intra-
venous cannula will be inserted and standard monitoring
applied, and then based on the randomization, the anaes-
thetist will perform either an ultrasound guided BPB as
necessary or ask the operating surgeon to undertake local
anaesthetic infiltration.
Patients in the Ultrasound Guided BPB group will
receive an ultrasound guided brachial plexus block. A
supraclavicular block will be performed unless there is a
contraindication, in which case an axillary block will be
used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% ligno-
caine with adrenaline (1 in 200,000) will be injected, using
a minimum of 25 mls and up to a volume of 40 ml [20].
Maximum dose limits of 2 mg/kg for bupivicaine and
7 mg/kg for lignocaine with adrenaline will be observed,
recognising that these are additive. The time taken to
perform the block and any technical problems during
block insertion will be recorded in the patient’s case report
file (intravascular puncture, paraesthesia). Measurements
of the sensory block of the musculocutaneous, median,
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minutes by a non-blinded observer using a previously
validated 3-point scale using a cold test: 0 = no block, 1 =
analgesia (can feel touch but not cold) and 2 = anaesthesia
(patient cannot feel touch) [21]. Motor block of the
musculocutaneous, median, radial and ulnar nerves will
be graded using a previously validated scale as either 0 =
no block, 1 = paresis, 2 = paralysis [21]. Measurements
will be continued until either the sensory block is ad-
equate in the operative area distribution or a maximum of
20 minutes has elapsed at which point the block will be
supplemented by targeted axillary or midhumeral supple-
mentation as appropriate using ultrasound. If a BPB block
fails despite supplementation, LA infiltration will be used.
This will be recorded as a failed block. If intravenous
opioid analgesia is required for operative site discomfort,
the BPB will be recorded as a failed block. Anaesthetists
performing ultrasound guided BPBs in this study will have
been deemed competent to perform this technique by the
principle investigator.
Patients in the Local Anaesthetic Infiltration group will
receive infiltration of local anaesthetic into the surgical site
by the operating surgeon under sterile conditions using a
combination of 0.5% L-bupivicaine prior to incision and
1% lignocaine topically after the wound is opened. Max-
imum dose limits of 2 mg/kg for bupivicaine, and 3 mg/kg
for lignocaine will be observed, recognising that these are
additive.
Using the technique described above, at the points
marked on the skin the internal diameters of the cephalic
and basilic veins will again be measured. Because after a
successful BPB patients will generally have an immobile,
vasodilated, warm arm, blinding from this stage will be
difficult. The average of three measurements at each pos-
ition will again be calculated. Similarly, the arterial blood
flow will be measured by Doppler ultrasound as described
previously, and again the average of three measurements
will be recorded. The veins and artery at the proposed
surgical site will also be examined and mapped using
ultrasound by the surgeon. The operating surgeon will use
this information to decide on the final site for the fistula.
Any deviation from the pre-operative plan based on
anatomical information obtained using ultrasound at this
stage will be recorded.Blinding
The allocation sequence will be accessed only when
study data collection is complete or in any instance
where unblinding of the study is thought to be essential
in the provision of appropriate patient care. Due to the
nature of the BPB and LA techniques, blinding of the
patient, operating surgeon and observer measuring imme-
diate post-anaesthetic flows is not possible. All furtherpost-operative measurements, including the primary
outcome, will be undertaken by a blinded observer.
Intra-operative management
The anaesthetist looking after the patient in theatre will
play no part in data analysis and will record the intra-
operative proceedings as normal. The medications used to
perform the two potential procedures will not be recorded
on the anaesthetic chart. The patient’s participation in this
study and the two possible anaesthetics that may have
been received will be documented on the anaesthetic chart
using a pre-made sticky label. Documentation of the
anaesthetic procedures, including adverse events, will be
kept in the patient’s case report file. The randomisation
code may be accessed if deemed necessary in the provision
of optimal patient care.
The patient will receive sedation if required and as
directed by the anaesthetist. All medications, with the
exception of the medications used to perform the BPB
or local anaesthetic infiltration, will be detailed in the
anaesthetic record.
All AVF procedures will be carried out at either the
wrist, forearm or antecubital fossa. A radio-cephalic AVF
will be fashioned through a longitudinal or equivalent inci-
sion and brachiocephalic AVFs fashioned using a horizon-
tal or equivalent incision. Heparinized saline may be used
to distend the vein. After sufficient mobilisation of the
vein, an end-to-side or side-to-side anastamosis will be
created using 6.0 or 7.0 non-absorbable suture. AVF
patency peri-operatively will be confirmed by palpating
for a thrill and listening for a bruit. If at this stage there
is no evidence of patency, this will be recorded and
surgical revision urgently undertaken if appropriate.
Postoperative management
After surgery, patients will be taken to the recovery
room and monitored according to standard hospital
policy. Patient satisfaction and pain during the procedure
will be assessed at this point. Patients will be discharged if
they meet day surgery criteria as per hospital policy.
At a time period of one month, three months and one
year, a blinded observer will examine AVF clinical patency
by palpating for a thrill and auscultating for a bruit. At all
these time points patients will be attending routine follow-
up clinics or have commenced haemodialysis. Lack of
both a thrill and a bruit will result in the fistula being
defined as not patent. At the same time, brachial artery
volume flow will be measured (as a surrogate for AVF
flow) by a blinded observer using Doppler ultrasound as
described previously. An average of three measurements
will again be made in order to reduce both intra and inter-
observer variation. Measurement of brachial artery flow is
more reproducible than AVF flows and less prone to
intraobserver variability [22]. The probe will be positioned
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anastamosis. The point of measurement will be recorded
and measurements at three months and one year made
at the same position. A minimum of six weeks after
AVF creation will be allowed to elapse before the first
venipuncture for HD. The flow during the first cannula-
tion of the fistula will be recorded by a blinded observer
in the renal patient registry, and also at three months
and one year if HD has been commenced at these time
points. Finally, at each time point of one and three
months and one year it will be noted by a blinded observer
if there has been any infection of the AVF requiring
antibiotics.
Criteria for discontinuation
Every effort will be made to retain patients in the trial
and to minimise withdrawals. However, any severe or
life-threatening event will be sufficient to remove a pa-
tient from the study. Failure of either procedure is likely
to result in the patient being given a general anaesthetic
and, hence, being withdrawn from the study. Patients may
request to be withdrawn from this study at any time. Rea-
sons for withdrawal will be documented. Intention to treat
and “as treated” analyses will be performed.
Data collection
Data will be obtained from the anaesthetic record, recov-
ery room observation chart, from clinical review in the
post-operative period and from the electronic renal patient
registry. Patient demographics, including age, gender,
ethnicity, weight, body mass index and co-morbidities, as
well as the surgeon, site of AVF (that is, distal or proximal
arm), type of anastomosis (that is, end-to-side or side-to-
side), duration of surgery, the type of anaesthesia used and
fistula outcomes, will be recorded in the case report form.
The researcher will be blinded to the technique used. Data
will be anonymised. Case report files will be archived in a
locked facility for a period of five years.
Sample size and statistical considerations
Mean AVF failure after formation is reported to lie within
the range 25 to 35% [4]. From our own retrospective audit
data of patients receiving an ultrasound guided BPB over a
two-year period, patients who had received BPB had an
AVF survival rate of 93% compared with 52% in patients
who received local anaesthetic infiltration [23]. In order to
calculate sample size, we made the following assumptions:
type 1 error (α) was set at 0.05 and Type 2 error (β) at 0.8.
Therefore, if we assume a standard 65% AVF success rate
overall, and propose that success rates with the use of BPB
will be around 85%, then 57 patients are required in each
group. In order to account for attrition of around 10%, we
aim to recruit 126 patients. It should be noted that whilst
these audit data were significantly in favour of the BPB,the data were retrospective, with non-standardised end-
points and also suffered from all the standard limitations
of a retrospective analysis.
The null hypothesis (H0) for this study is that the use of
ultrasound guided brachial plexus block does not reduce
AVF primary failure rate when compared with local anaes-
thetic infiltration.
The study will be performed using both intention to
treat and “as treated” analysis. In the intention to treat
analysis, data will still be analysed from patients where the
block has failed (that is if local anaesthetic supplementa-
tion is required), or if the patient was unable to receive
randomised treatment for any other reason. In the “as
treated” analysis, only data from patients completing
randomised treatment will be analysed.
Secondary data analyses will be carried out on all sec-
ondary outcomes. These will be compared between groups
using t-test and Mann–Whitney, or Chi-squared tests as
appropriate.
It is anticipated that recruitment for this study will take
up to two years to complete if one to two patients are
enrolled each week. Data collection for each patient will
occur during the operative and immediate post-operative
period, and at dialysis sessions and post-operative follow-
up as directed by the vascular team for one year.
We recognise that while this study is powered for the
primary outcome, it is not powered for all the secondary
outcomes. Whilst other studies suggest that our study is
in fact overpowered for the secondary outcome of flow
rate, this may not confer a clinical benefit, unlike our
primary outcome, which is the reason this outcome has
been selected. Any secondary data we collect in this
study will provide useful information for further studies
looking specifically at these outcomes.Adverse event reporting and safety
All adverse events will be fully recorded in the medical
records and on the study record forms and discussed at
monthly safety meetings by at least two investigators.
Adverse events will be monitored and followed up until
satisfactory resolution or stabilization. If clinically indi-
cated, the nature of the anaesthetic administered in the
study may be revealed. After assessment of adverse
events by the principal investigator for seriousness,
causality, expectedness and severity, any serious adverse
events (SAEs) will be reported to the main Research and
Ethics Committee and the sponsor where in the opinion
of the principal investigator the event was related
(resulted from administration of any of the research
procedures) and unexpected (not listed in the protocol
as an expected outcome). SAEs will be reported using the
National Research Ethics Service SAE report form for
non-Clinical Trials of Investigational Medical Products.
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safely used for a wide variety of surgeries, although, as
with all techniques, rare risks exist. Rare risks, however,
are also associated with general anaesthesia and because
these are increased in patients with end stage renal failure,
we expect that all patients will benefit through avoidance
of a general anaesthetic. Unlike the local infiltration group,
patients in the BPB group are at risk of nerve damage.
This is a well-recognised complication of regional anaes-
thesia. Rates of temporary nerve damage for peripheral
nerve blocks are reported in some studies to be as high
as three percent [24]. Reassuringly, in this large review
of many prospective and retrospective case series, the
authors found no evidence of permanent damage. The
frequency reported in other large case series was less
frequent [25]. Nevertheless, nerve damage remains one
of the most concerning risks of regional nerve blocks.
Whilst in some studies this can be balanced against the
benefit of avoiding the rare risks of general anaesthesia,
in our study both groups will avoid general anaesthesia.
The risk of nerve damage may be reduced by using
ultrasound to guide needle placement. Ultrasound allows
direct visualisation of the target nerve, needle and local
anaesthetic spread and can detect small intraneural injec-
tions, but not intrafascicular injection, which appears to
be most harmful [26]. Whilst ultrasound use appears to
improve block success [27,28], it has not yet been proven
to reduce the incidence of nerve damage. Indeed, nerve
damage may still occur whilst ultrasound is in use [29].
Ultrasound has been shown, however, to reduce vascular
puncture and allow use of smaller local anaesthetic vol-
umes, the combination of which is important in reducing
the risk of systemic local anaesthetic toxicity, which is the
other serious but rare complication of regional anaesthesia
[28,30]. Any adverse events relating to the procedure will
be recorded by staff performing the study and necessary
investigations, treatment or follow-up arranged thereafter.
Conclusions
The purpose of this trial is to investigate the hypothesis
that long-term AVF patency is improved by a BPB com-
pared to local anaesthetic infiltration as this has not yet
been demonstrated in a large randomised controlled
trial. Reducing the AVF failure rate is of significant
benefit by increasing the number of patients able to
commence HD when planned and reducing the number
of “redo” procedures. This has clear financial benefits
and also reduces the inconvenience to patients and the
risks of further AVF surgery. If, however, our null
hypothesis is correct, this finding would still provide
useful information. LA infiltration is simpler, less time
consuming and avoids the rare risks of brachial plexus
blocks. LA infiltration also bypasses the financial and
practical implications of requiring an anaesthetist toundertake the block, and monitor the patient. Therefore,
either a positive or negative result will help inform future
anaesthetic practice regarding the surgical creation of
arteriovenous fistulae.
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